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Lesions of Testis and Epididymis
Associated with Prenatal Diethyistilbestrol
Exposure
by Bill C. Bullock,* Retha R. Newbold,* and John A.
McLachlan*t
Cryptorchidism and retention ofMullerian duct structures occur with high frequency among the male
offspring of CD-1 mice treated with 100 ,ug diethylstilbestrol/kg body weight on days 9 through 16 of
pregnancy. Hyperplasia ofthe rete testis and Mfillerian duct structures were found in many ofthe DES-
treated male mice, as was a low but significant number of reproductive tract neoplasms.
This is a briefreview ofsome developmental changes
in the male mouse reproductive tract associated with
in utero exposure to a synthetic estrogen, diethylstil-
bestrol (DES).
The knowledge that estrogenic compounds affect the
early differentiation and development of the male re-
productive tract has been evident for about 50 years;
however, the full range of morphological changes has
begun to emerge only recently. Interest in the subject
has been promoted by the finding of rare gynecologic
cancers in daughters ofwomen given DES while preg-
nant, as well as epididymal cysts, cryptorchidism, and
testicularneoplasms amongthe sonsofwomenreceiving
DES duringpregnancy. Because DESis effective when
taken orally and is relatively stable, it provides a model
for the study of estrogenic compounds in the environ-
ment. Background information is provided in several
reviews (1-3).
Perhaps one of the most important developmental
effects of exogenous estrogen on the male mouse re-
productive tract is cryptorchidism. Administration of
estrogenic substances to pregnant mice or to neonatal
mice has become afrequently used modelto studycryp-
torchidism (4). Cryptorchidism is not an insignificant
problem among men; it is one ofthe most frequent in-
dications for pediatric surgery, and in some studies, 2
to 3% offull-term male infants have been found to have
retained testes. It is even more frequent among pre-
mature male infants (4).
The results summarized here have been derived from
the study ofoffspring ofCD-1 mice treated with 100 ,ug
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DES/kgbodyweight ondays 9through 16ofpregnancy
(5-9).
We have chosen not to deal at length with the subtle
hypoplastic and degenerative changes associated with
cryptorchidism; the well-known testicular changes in-
clude incomplete maturation of spermatozoa, atrophy
ofthe seminiferous tubules withthickeningofbasement
membranes, and interstitial fibrosis. Some intra-ab-
dominal testes were infarcted, perhaps due to torsion,
and others were reduced to fibrotic nodules with few
recognizable features. In a study that involved 277
DES-treated and 122 control mice (10-18 months old),
91% (252/277) of the treated mice had at least one re-
tained testis, 8% had inflammation, and 82% had some
degree of degenerative change in the testis. The de-
generative changes were categorized by increasingly
severe morphological changes which are as follows: (a)
relatively normal appearing testes that were smaller
than controls, (b) testes with substantially reduced
spermatogenesis, containing giant cells within the lu-
mina of the seminiferous tubules, (c) testes composed
ofatrophied seminiferous tubules withhyalanized base-
ment membranes and thickened arterioles, and (d)
testes composed mostly of necrotic or scar tissue with
the absence of spermatogenesis. The 82% incidence of
degenerative changes in male mice includes those from
categories b, c, and d.
Inadditiontoretainedtestesanddegenerativechang-
es, two (1%) ofthe male mice exposed in utero to DES
hadinterstitial celltumors, andfive (2%)hadinterstitial
cellcarcinomasofthetestis. Noneofthesechangeswere
found among control animals in this study (9).
Some strains oflaboratory animals, most notably the
Fischer 344 rat, have a high prevalence of interstitial
cell tumors, but these tumors rarely, if ever, metas-BULLOCK, NEWBOLD, AND MCLACHLAN
Table 1. Rete testis lesions in male mice exposed prenatally
to diethylstilbestrol (6).a
Lesion Control DES-100
Hyperplasia 23/96 (24)b 130/233 (56)*
Adenocarcinoma 0/96 (0) 11/233 (5)t
aMales were the 10- to 18-month-old offspring ofCD-1 mice treated
with DES (100 ,g/kg body weight, injected SC on days 9-16 ofges-
tation). As there was not a statistically significant difference in prev-
alence oflesions with age, rete testis hyperplasia and lesions resem-
bling adenocarcinoma in each age group have been combined.
bNumbers in parentheses are percentages.
*Statistical significance of DES-exposed animals to corresponding
age-matched controls by the Fisher exact test, p < 0.001.
tp < 0.05.
Table 2. Abnormalities in male mice exposed prenatally
to diethylstilbestrol (8).a
Abnormality Number of animals
Mukllerian remnantsb
Prominent structure 268/277 (97)C*
Cystic structure 121/277 (44)*





Cystic epididymis 32/277 (12)*
Inflammation 87/277 (29)*
Sperm granuloma ofepididymis 16/277 (6)*
Hyperplasia of epididymal duct 1/277 (0)
Tumorf 1/277 (0)
aMales were the 10- to 18-month-old offspring ofCD-1 mice treated
SC with DES (100 ,ug/kg) on days 9-16 ofgestation.
bSquamous metaplasia and gland function in male Mullerian rem-
nants are not included in the table because of low incidence.
cNumbers in parentheses are percentages.
dTumors ofMullerian remnants are described in Table 3.
eAt 18 months of age, the control animals had minor inflammatory
changes in Wolffian derivatives. One 18-month-old control animal had
severeinflammation oftheepididymis andanotheranimalhadaspern
granuloma. No otherlesions were observed in the control 122 animals
at any age in this study.
flTumor in the Wolffian derivatives was adenoma ofthe epididymis.
*Statistically significant difference between DES-exposed animals
and corresponding controls; Fisher exact test p < 0.05.








Complex stromal sarcoma 1
Adenocarcinoma 1
aMales were the 10- to 18-month-old offspring ofCD-1 mice treated
SC with DES (100 ,ug/kg) bodyweight ondays 9-16 ofgestation. The
total number of DES-100 males observed in this study was 277.
tasize. In mice, however, some interstitial cell tumors
are considered malignant and distant metastases have
been reported (10). Interstitial cell tumors in control
CD-1 mice up to the age of 18 months are quite rare.
We have not found these tumors in the control mice in
anumber ofstudies. Although the numberofneoplasms
in DES-treated animals was low, the proportion with
features consistent with malignancy (irregular edges,
necrosis, hemorrhage, invasion of blood vessels, and
extension into the spermatic cord) was high (9).
Subgroups of animals (96 control, 233 DES-treated)
were identified on the basis ofhaving adequate sections
of the rete testis for study. As there was little back-
ground information on proliferative lesions of mouse
rete testis, a conservative approach was taken in that
any piling up of cells in the rete testis of control males
was termed "hyperplasia," whereas amore rigorous re-
quirement of a multifocal or diffuse change was placed
on DES-treated animals. Theresultsare showninTable
1.
In addition to the statistically significant increase in
hyperplasia in DES-treated animals, neoplasms of the
retetestis occurred in 11 of233mice (5%). These lesions
had the morphological features ofhuman rete testis ad-
enocarcinomas, usually being papillary, but sometimes
with tubular or sertoliform appearing areas.
The embryonic origin of the rete testis and Sertoli
cells has been a matter ofcontroversy. Byskov reports
that the rete testis is probably derived from the me-
sonephricsystem(11); reviewingherownworkandthat
of others, she concluded that some, if not all, Sertoli
cells are also derivedfromthemesonephros. Thiswould
be consistent with our finding of occasional rete testis
neoplasms that have some features of Sertoli cell neo-
plasms (12).
One ofthemore strikingfindings amongDES-treated
animals is the persistence of Mullerian structures re-
sembling portions of the mature female reproductive
tract. Cystic Mullerian structures with oviduct-type ep-
ithelium frequently were found adjacent to the epidi-
dymal duct. The range of cystic and proliferative
changes seen in these Mullerian remnants, which re-
sembled all portions of oviduct and uterus, are sum-
marized in Table 2.
In normal development of the male reproductive
tract, a small portion of the Mullerian duct sometimes
persists to form appendix testes and prostatic utricle.
However, persistence of the Mullerian duct is a usual
occurrence in CD-1 mice that received DES in utero;
the fimbria ofthe oviduct in these animals is largerthan
the appendix testes of control animals, and the homo-
logues of the oviduct and uterus in males may occa-
sionally exceed the size of the normal structures in fe-
male mice. Pathological changes may develop in these
male homologues of the oviduct and uterus (8). These
benign and malignant proliferative lesions are summa-
rized in Table 3.
A substance produced by Sertoli cells, called Muller-
ian inhibiting substance (MIS) (13) or anti-Mullerian
hormone (14), has an important influence on regression
of the Mullerian duct in males. The whole concept of
Mullerian duct regression is a subject of vigorous in-
vestigation, and the words "regression" and "persist-
ence" are probably oversimplifications. In heterotypic
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organ culture, testes from DES-treated male fetuses
cocultured with Mullerian ducts from normal animals
were capable of producing regression, but Mullerian
ductsfromDES-treated animalscoculturedwithnormal
testes did not regress (15). This suggests a defect in the
ability ofthe DES-exposed reproductive tract tissue to
respond to MIS. A persistent Mullerian duct syndrome
has been described in human males, usually associated
with cryptorchidism and Leydigcell hyperplasia. These
men may have uteri, oviducts, and the upper one-third
of the vagina (16).
In summary, the occurrence of several types ofrare
neoplasms in the male offspring of mice that received
DES during pregnancy suggests that although the neo-
plasms are expressed later in life, interference with
normal development at an early stage maybe necessary
for their development.
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